Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amylin Pharmaceuticals LLC    AMLN   US0323461089

SummaryQuotesChart AnalysisNewsCompany 
News SummaryMost relevantAll news 

Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin

03/23/2012 | 08:54am US/Eastern

Amylin Pharmaceuticals Inc. (>> Amylin Pharmaceuticals, Inc.) and Eli Lilly & Co. (LLY) said the European Commission approved its type 2 diabetes treatment Byetta as an add-on therapy to basal insulin.

The drug makers said Byetta with titrated basal insulin improves glycemic control after meals, and common side effects include nausea, diarrhea, dizziness and headache.

Lilly and Amylin in November severed their nine-year-old partnership that was supposed to furnish a blockbuster treatment for diabetes but was instead plagued by disappointing sales, regulatory troubles and company disputes, The Wall Street Journal reported. Amylin agreed to pay $250 million to Lilly upfront and as much as $1.2 billion more from sales of a molecule called exenatide that lowers the blood sugar of diabetics. That molecule is in the drug Byetta.

Amylin on Friday said it will assume responsibility for exenatide-product commercialization outside of the U.S. on a market-by-market basis by the end of 2013. During the transition period, Amylin will work with Lilly on plans for markets outside the U.S.

Amylin and Lilly shares closed Thursday at $15.41 and $39.81, respectively. Both were inactive premarket.

 
   -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com 

Stocks mentioned in the article : Amylin Pharmaceuticals, Inc.
Latest news on AMYLIN PHARMACEUTICALS LLC
2012 AMYLIN PHARMACEUTICALS, INC. : Bristol-Myers Squibb and AstraZeneca Complete Exp..
2012DJEli Lilly To Record $1.26 Billion Benefit from Amylin
2012DJASTRAZENECA : Bristol-Myers Squibb Completes Purchase of Amylin
2012DJBristol-Myers Executive Charged With Insider Trading
2012DJBristol-Myers Executive Charged With Insider Trading
2012DJBristol-Myers Executive Charged With Insider Trading
2012 Bristol-Myers executive charged with insider trading
2012DJU.S. Charges Bristol-Myers Executive With Insider Trading
2012DJBristol-Myers Pension Executive Robert Ramnarine Arrested for Alleged Insider..
2012DJEvercore 2nd-Quarter Profit Climbs 19% On Higher Investment Banking Revenue
Advertisement
Chart
Duration : Period :
Amylin Pharmaceuticals LLC Technical Analysis Chart | AMLN | US0323461089 | 4-Traders
Dynamic quotes  
ON
| OFF